Stryker launches Gamma4 Hip Fracture Nailing System in Europe

Rhea-AI Summary

Stryker (SYK) launches Gamma4 Hip Fracture Nailing System in European markets, enhancing surgical workflows with advanced features. The system received CE certification, offering improved usability and anatomical fit for femur fractures treatment.

Insights

Orthopedic Surgeon

The introduction of Stryker's Gamma4 Hip Fracture Nailing System presents a significant advancement in the field of orthopedic surgery. The system's design, which is informed by a substantial SOMA database, implies a tailored approach to intramedullary nailing that could potentially enhance the anatomical fit for patients. A chamfered distal tip and a shorter proximal body are indicative of a nuanced understanding of bone morphology, which could translate into improved surgical outcomes and reduced recovery times for patients suffering from hip and femur fractures.

Furthermore, the length-dependent radius of curvature for longer nails may suggest a more natural alignment within the femur, potentially reducing stress on the bone and the implant. The Precision Pin™, with its increased resistance to pull out and reduced skiving, points towards a reduced risk of intraoperative complications, which is a critical factor in successful patient outcomes. As an orthopedic surgeon, the integration of these features could signify a stride in our ability to provide more reliable and patient-specific care.

Medical Device Market Analyst

The release of Stryker's Gamma4 system in the European market is a strategic move that could strengthen the company's position in the global orthopedic device industry. The CE certification indicates that the product meets the European Union's safety, health and environmental protection requirements, which is an essential step for market penetration. Stryker's established presence in North America and Japan, with over 25,000 cases already utilizing the Gamma system, demonstrates a proven track record that may facilitate adoption in Europe.

From a market perspective, the aging population in Europe is likely to increase the prevalence of osteoporotic and osteopenic bone conditions, leading to a higher demand for hip and femur fracture treatments. The Gamma4 system's improved features, such as the redefined nail design and integrated instrument platform, cater to this growing market by offering enhanced usability and streamlined surgical procedures. This could result in cost savings for healthcare providers and improved turnover rates for surgeries, potentially impacting Stryker's sales and market share positively.

New system streamlines workflows and enhances usability

AMSTERDAM--(BUSINESS WIRE)-- Stryker (NYSE:SYK), a global leader in medical technologies, today announced the release of its Gamma4 Hip Fracture Nailing System in most of the European markets. The newest Gamma system will provide surgeons with the next generation of Stryker’s intramedullary nailing system. The Gamma4 system is designed to treat hip and femur fractures and streamline procedural workflows for surgeons. The system received the CE certification in Europe in September 2023.

The Gamma4 System is indicated for the treatment of fractures in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). (Photo: Business Wire)

“The Gamma4 system represents the latest chapter of the Gamma legacy, and we are excited to expand availability to our European customers after a successful launch in the U.S.,” said Markus Ochs, vice president and general manager of Stryker’s European Trauma & Extremities division. “This latest system demonstrates our commitment to working together with our customers to understand their needs. With evolved features to the trusted Gamma system, we believe the system will help our customers rebuild patient lives.”

Used in over 25,000 cases in North America and Japan, the Gamma4 System is indicated for the treatment of fractures in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). Key features include:

• A redefined nail design. Designed using our SOMA database of over 34,000 3D bone models generated from CT scans¹, Gamma4 has a chamfered distal tip, a 5mm shorter proximal body compared to Gamma3, and a length-dependent radius of curvature (RoC) for long nails², enhancing anatomical fit and usability.
• Improved workflow. The Precision Pin™ offers more resistance to pull out, and the potential for skiving is reduced by 66% compared to a standard ∅3.2 K-wire.³
• Integrated instrument platform. Gamma4 and T2Alpha nails now all work on the same instrument platform, standardizing surgical procedures.

“The Gamma system has evolved through streamlined processes, standardization and meticulous attention to detail, all crafted to elevate operative techniques and enhance usability,” said Dr. Gilbert Taglang, chairman of the OTCF Education Committee. “With an unwavering focus on surgeon experience and feedback, our goal was to not only enhance ease of use but also prioritize the well-being of the patient. The new Gamma4 system redefines hip fracture care with sleek instrumentation, advanced nail design and improved geometry collectively, ensuring a lasting impact on orthopaedic practices for years to come.”

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.

Content ID: G4-AD-13, 02-2024

References

1. Internal report D0000124129, Rev AD
2. Internal Report № D0000089997, Rev AA
3. Stryker: Internal test report D0000099352, Rev AE

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326868923/en/

Media Contact

Andrea Sampson

President/CEO, Sampson Public Relations Group

asampson@sampsonprgroup.com

562.304.0301

Source: Stryker

FAQ

What did Stryker (SYK) announce in the press release?

Stryker announced the release of its Gamma4 Hip Fracture Nailing System in most European markets.

What is the key feature of the Gamma4 System?

The key features include a redefined nail design, improved workflow, and an integrated instrument platform.

Where can the full release be viewed?

The full release can be viewed at the following link: https://www.businesswire.com/news/home/20240326868923/en/

What regions of the femur does the Gamma4 System treat?

The Gamma4 System treats fractures in the intracapsular, trochanteric, subtrochanteric, and shaft regions of the femur.

Who is the vice president and general manager of Stryker's European Trauma & Extremities division?

Markus Ochs is the vice president and general manager of Stryker's European Trauma & Extremities division.